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Eukaryotic translation initiation factor 5A (eIF-5A) is the only known cellular protein 
that contains the post-translationally derived amino acid, hypusine. Initially, eIF-5A was 
named as a translation initiation factor because of its capability to stimulate the formation of 
methionyl-puromycin, which mimics the first peptide bond formation during protein 
synthesis, under in vitro conditions. Subsequently, however, this proposed function of eIF-
5A has been questioned because a similar effect on translation was not observed in situ. 
Moreover, eIF-5A appears not to be required for general protein synthesis. Rather, there is 
evidence that it facilitates the translation of specific subsets of mRNAs required for cell 
proliferation as well as apoptosis.  
There are two isoforms of eIF-5A in the human genome which have designated eIF-
5A1 and eIF-5A2. The objective of the present study was to gain an increased understanding 
of  the roles of eIF-5A1 and eIF-5A2 during apoptosis and cell proliferation using human cell 
lines as a model system. Apoptosis was induced by treating the cells with Actinomycin D or 
sodium nitroprusside (SNP), which initiate programmed cell death by different mechanisms. 
It was observed for both normal and cancer cells that eIF-5A1 protein is up-regulated during 
apoptosis induced by Actinomycin D or SNP, whereas eIF-5A1 mRNA is constitutively 
expressed and does not change in abundance  during this treatment.. The up-regulation of  
eIF-5A1 protein levels in the absence of a corresponding up-regulation in eIF-5A1 mRNA 
suggests that eIF-5A1 may be post-transcriptionally regulated. Moreover, eIF-5A1 protein 
up-regulation was stronger in normal cells than in cancer cells. By contrast, eIF-5A2 protein 
was below detection levels during apoptosis in both normal and cancer cells, although the 
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corresponding transcript was detectable by semi-quantitative RT-PCR. This is attributable to 
inefficient translation of eIF-5A2 mRNA.  
The effects of eIF-5A1 and eIF-5A2 on cell proliferation were examined by 
modulating the levels of serum in cultures of UACC-1598 cells, which are ovarian cancer 
cells that express high levels of both isoforms of eIF-5A.  Serum starvation, which induces 
cell cycle arrest and ensuing apoptosis, followed by the re-addition of serum  had no effect 
on  the transcript levels of either eIF-5A1 or eIF-5A2. However, eIF-5A1 and eIF-5A2 
proteins were both  up-regulated  within 24 hours of the initiation of  serum starvation, and 
this coincided  temporally with the onset of apoptosis as measured by TUNEL and a 
subsequent decline in viable cells.  
The data indicate that eIF-5A1 and eIF-5A2 are both post-transcriptionally regulated 
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The term “apoptosis” was coined by Kerr et al. (1972) to describe the “falling off” of 
leaves from trees or petals from flowers.  This meaning coincides with the particular 
morphology of apoptosis or programmed cell death.  
Apoptosis can be differentiated from necrosis, which is another form of cell death. 
Necrosis occurs in response to injury by toxins, physical stimuli, or ischemia. Swelling of 
cells, disruption of membranes and  lysis of nuclear chromatin are the hallmarks of necrosis, 
whereas shrinkage of cells, blebbing of membrane, condensation of the nucleus  and 
formation of apoptotic bodies are the characteristic features of apoptosis (Saikumar et al., 
1999). Apoptosis has significant importance in various processes such as development, 
morphogenesis, homeostasis, and deletion of damaged cells. Dysfunction or dysregulation of 
the apoptotic program is associated with various pathological conditions (Fadeel et al., 1999). 
Tumor formation and metastasis are consequences of a defective apoptotic pathway 
(Jhonstone et al., 2002). Indeed, there is strong evidence that tumorigenesis is not only the 
result of excessive proliferation due to the activation of oncogenes, but also impairment of 
apoptosis pathways (Hanahan and Weinberg, 2000). 
 
1.2 Transformation of normal cells into cancer cells 
The development of a cancer cell from a normal cell is a multistep process driven by 
a series of somatic mutations. This has been demonstrated in human colon cancer, which 
progresses in a series of well-defined morphologic stages. Figure 1 illustrates a model of 
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colon cancer where a sequence of gene changes occurs including inactivation or loss of three 
tumor-suppressor genes (APC, DCC and p53) and activation of an oncogene (K-ras). Various 
chemicals, such as DNA-damaging agents,  and physical agents including ultraviolet light are 
able to induce mutations. Induction of malignant transformation with chemical or physical 
carcinogens entails at least two distinct phases: initiation and promotion. Initiation involves 
changes in the genome, but does not in itself lead to a malignant phenotype. Rather, after 
initiation, promoters stimulate cell division leading to the malignant phenotype (Goldsby et 
al., 2003). 
 
1.3 Apoptotic pathways in normal cells: 
1.3.1 Extrinsic apoptotic pathways 
Extrinsic apoptotic signaling is initiated by the activation of death receptors that 
transmit apoptotic signals upon ligation with specific ligands including TNFR1, Fas, and 
TRAIL (Ashkenazi, 2002) (See Figure 2). Signals originating from death receptors activate 
the Death Inducing Signaling Complex (DISC), which in turn mediates activation of the 
initiator caspase-8. Caspase-8 initiates a caspase cascade by activating the effector caspases-
3, 6, and 7, which results in cleavage of caspase substrates. Finally, cleavage of caspase 
substrates leads to the morphological and biochemical features of apoptosis. Cells able to 
induce this mainly caspase-dependent apoptosis are termed type I cells (Scaffidi et al., 1998). 
In some cells, the incoming signal from the DISC must be amplified via mitochondria-
















Figure 1. A model for colon cancer depicting transformation of a normal cell into a 


















































caspase signaling cascade and mitochondria is provided by the Bcl-2 family member, Bid. 
Bid is cleaved by caspase-8, and in this truncated form is translocated to the mitochondria. In 
mitochondria, Bid acts in association with the proapoptotic Bcl-2 family members, Bax and 
Bak, to  release cytochrome c into the cytosol (Luo et al., 1998). Cytochrome C initiates 
formation of the apoptosome,  which triggers activation of caspase-9 (Acehan et al., 2002). 
Finally, activated caspase-9 activates caspase-3, caspase-6 and caspase-7, which results in 
apoptosis (Denault and Salvesen, 2002).  
1.3.2 Intrinsic apoptotic pathways 
Intrinsic stresses such as DNA damage can activate the intrinsic apoptotic pathway 
(See Figure 2). As a sensor of cellular stress, p53 is a critical initiator of this pathway (Lowe 
and Lin, 2000). p53 can initiate apoptosis by transcriptionally activating proapoptotic Bcl-2 
family members, such as Bax and  Bak, and by repressing antiapoptotic Bcl-2 family 
members such as Bcl-2, Bcl-XL (Bartke et al. 2001). However, p53 can also transactivate 
other genes that may contribute to apoptosis such as PTEN (Hwang et al. 2001). Moreover, 
p53 can transcriptionally activate various death receptors and sensitize cells to death-
receptor-mediated apoptosis (Herr and Debatin 2001). Therefore, it appears that p53 is 
capable of coordinating the apoptotic program at multiple levels via several mechanisms. 
Still, p53 is not the only activator of the intrinsic apoptotic pathway. Some studies suggest 
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1.3.3 Role of mitochondria in the apoptotic pathway:  
Mitochondrial membrane permeabilization in an important factor in apoptosis 
induction, which is regulated by the opposing actions of pro- and antiapoptotic Bcl-2 family 
members. The BH3-only  protein, Bid, can directly interact with proapoptotic Bcl-2 proteins 
(e.g., Bax and Bak) and activate them. Alternatively, binding of other BH3-only proteins 
(e.g., Noxa, Puma, Bad, and Bim) to antiapoptotic Bcl-2 proteins (e.g., Bcl-2 and Bcl-XL) 
results in activation of Bax and Bak (Adams and Cory 1998 and Huang and Strasser 2000). It 
is not clear whether Bcl-2 proteins control mitochondrial membrane permeability by directly 
forming pores in the outer membrane, or by regulating the opening and closing of the 
permeability transition pore (Martinou and Green, 2001). However, the consequence is 
regulated release of proapoptotic factors from the mitochondria, induction of downstream 
caspases, and  loss of mitochondrial function. Another important mitochondrial proapoptotic 
factor is Smac, which is released from mitochondria and acts by inhibiting the antiapoptotic 
proteins termed IAPs (inhibitors of apoptotic proteins). IAPs can directly inhibit caspases. 
Smac inhibits IAPs from blocking caspase activity (Du, 2000). 
1.4 Dysregulated apoptotic pathways in cancer cells 
1.4.1 Dysregulation of the intrinsic apoptotic pathway:  
Disruption of the intrinsic apoptotic pathway is extremely common in cancer cells. 
The p53 tumour suppressor gene is the most frequently mutated gene in human tumors. Loss 
of p53 function impairs apoptosis and accelerates tumor development in transgenic mice 
(Attardi and Jacks 1999 and Ryan et al. 2001).  In addition, mutations of p53 downstream 
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effectors, such as  PTEN, Bax, Bak, and Apaf-1, are  common  in human tumors. Therefore, 
the presence of wild-type p53 does not necessarily indicate that the pathway is intact 
(Schmitt et al., 1999). 
Bcl-2 family members, which also regulate the intrinsic pathway, have been shown to 
be altered in tumor samples as well. In fact, Bcl-2, which is a negative regulator of apoptosis, 
is over-expressed in a number of cancers (Reed, 1999). Moreover, Bcl-2 over-expression can 
accelerate tumor formation in transgenic mice (Adams et al. 1999). Conversely, proapoptotic 
Bcl-2 proteins are inactivated in certain cancers, and dysregulation of these proteins 
promotes tumor formation in mice (Datta et al., 1999).  
 
1.4.2 Dysregulation of the postmitochondrial death process: 
Mutation in apoptotic proteins that function downstream of mitochondrial 
cytochrome c has also been reported. For example, over-expression of IAPs, which inhibit 
caspase 9 activation, is commonly observed in human tumors (Deveraux and Reed 1999). 
However, post-mitochondrial mutation is less frequent than those mutations which target 
upstream components of the apoptotic pathway (Johnstone et al., 2002).  
1.4.3 Dysregulation of the death receptor pathway: 
Dysregulation in the death-receptor pathway occurs less frequently than dysregulation 
in the intrinsic pathway (Jhonstone et al. 2002). However, it is not uncommon for tumor cells 
to be resistant to death-receptor-mediated apoptosis, largely because of mutations in CD95, 
TRAIL receptors, and downstream signalling pathways activated by ligand association with 
death receptors. Mutations in CD95, for example, result in inappropriate survival of activated 
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T lymphocytes, which causes Autoimmune LymphoProliferative Syndrome (ALPS).  ALPS 
patients have an increased incidence of lymphoma,  probably due to the large population of 
apoptosis-resistant T cells (Straus et al., 2001). It is to be expected that dysregulation of the 
death receptor pathway would provide a survival advantage to developing tumor cells. This 
contention is supported by the finding that  loss of CD95L or TRAIL function promotes 
tumor growth and metastasis (Rosen et al. 2000 and Takeda et al. 2001). 
1.5 Cancer producing mutations 
Cancer producing mutations give rise to oncogenes and also commonly occur in tumor-
suppressor genes. 
1.5.1 Oncogenes 
Dominant mutations can generate oncogenes that exhibit abnormal activity or 
produce an excessive amount of protein. The wild type gene that becomes an oncogene is 
known as a protooncogene. Oncogenes typically cause abnormal cell proliferation, which 
may lead to the accumulation of more mutations eventually leading to cancer (Hartwell et al., 
2004). Oncogenes can be activated by point mutations that enhance the function of the 
oncoprotein (Downward et al., 2003). Other mechanisms of oncogene activation include 
chromosomal translocation, where a new fusion gene is transcribed into a protein with 
enhanced function. Oncogenes promote carcinogenesis through amplification and over-
expression. Amplification may include short chromosomal regions of chromosomal arms 
involving hundreds of genes or entire chromosomes (Osborne et al, 2004). 
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1.5.2 Tumor-suppressor genes 
Mutations of tumor-suppressor genes are typically recessive, resulting in expression 
of  normal protein when they are heterozygous with the wild type allele and mutant protein 
when they are homozygous (Hartwell et al., 2004). Tumor suppressor genes are often  
inactivated by chromosomal deletions (Kohno and Yokota, 1999). In some cases there is not 
a mutation in the tumor suppressor gene; rather some other factor interferes with its 
expression or the function. For example, methylation of the gene promoter which suppresses 
its transcription, an increased rate of proteasomal degradation, or abnormalities in other 
proteins that interact with the tumor-suppressor gene product are all factors that have been 
shown to disrupt tumor suppressor gene function (Osborne et al., 2004).   
1.6 Division of normal cells 
A number of genes and their cognate proteins control the cell cycle. These genes and 
proteins enable progression of the cell cycle from one stage to the next under normal 
conditions, and inhibit progression through the cell cycle in the event the cell is damaged and 
there is a need for repair (Hartwell et al., 2004).  
 
1.6.1 The Cell cycle 
The cell cycle has four phases: G1, S, G2, and M. G1 is the period between the end of   
mitosis and the initiation of DNA synthesis that precedes the next mitosis. S is the period of 
DNA synthesis,  whereas G2 is the gap between DNA synthesis and mitosis. M is the period 
when the breakdown of the nuclear membrane, condensation of the chromosomes, 
attachment of the chromosomes to the mitotic spindle, and segregation of chromosomes to 
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the two poles occur. At the end of mitosis, the cell divides (Hartwell et al., 2004). Entrance 
into the cell cycle and subsequent proliferation are tightly regulated, in part by cyclin-
dependent kinases (CDKs).  Upon activation, CDKs promote phosphorylation of other 
proteins, especially retinoblastoma protein (Rb), which allows the transition from a resting 
state into mitosis. Cyclin D1 and cyclin E play a key role in progression of the cell cycle 
from the G1 to S phase, and their expression levels oscillate as the cell cycle progresses 
(Vermeulen et al., 2003). When cyclin D1 is complexed with its respective CDK partner, the 
Rb protein is phosphorylated, which in turn releases the transcription factor, E2F, and 
induces proteins required for DNA synthesis (Loden et al., 2002). Additional controls in the 
cell cycle are known as checkpoints because they check the cell cycle machinery before 
allowing the cell to continue to the next phase of cell cycle (Hartwell et al., 2004). 
1.6.2 The G1-to-S Checkpoint 
DNA damage during G1 causes postponement of DNA replication, which allows time 
for DNA repair before the cell proceeds to DNA synthesis. In the event of DNA damage, G1 
delays entry into S phase by activating p53, which induces expression of DNA repair genes 
(Hartwell et al., 2004).  
1.6.3 The G2-to-M Checkpoint 
DNA damage during G2 delays mitosis, which allows time for repair before 
chromosome segregation (Hartwell et al., 2004). 
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1.6.4 A checkpoint in M 
This checkpoint oversees formation of the mitotic spindle and proper engagement of 
all pairs of sister chromatids. As chromosomes condense and attach to the spindle, sometimes 
a single chromosome fails to attach at the expected time. In this case, the cell does not initiate 
sister chromatid separation until the lagging chromosome attaches to the spindle (Hartwell et 
al., 2004).  
1.7 Dysregulated cell cycle in cancer cells 
Many genes that contribute to the normal control of cell division are subject to 
mutations. Such mutations cause malfunctions in the CDK-cyclin complexes or in the 
checkpoints. Table 1 lists some cell-division genes in which mutations contribute to cancer 
(Hartwell et al., 2004).  
The gene encoding cyclin D1 has been found to be over-expressed in 40%–50% of  
breast cancers (Steeg and Zhou, 1998), and high cyclin D1 expression is positively associated 
with an increased proliferative index (Loden et al., 2002). Like cyclin D1, over-expressed 
cyclin E in cancer cells results in hyperphosphorylation of Rb protein and increased 
proliferative activity. However, high cyclin E- tumors are able to induce DNA synthesis 
independently of  Rb phosphorylation and E2F activation. The consequence is a marked 
reduction in cell cycle control and a significant dysregulation of proliferation (Loden et al., 
2002 and Keyomarsi and Pardee, 2003). Furthermore, mutations in the  tumor suppressor 
gene, p53, disrupt the G1-to-S checkpoint. Faulty p53 allows cells carrying damaged DNA to 


































Genes Gene products and their functions 
CDK4 A CDK of mammalian cells important for G1 to S transition 
CDK2 A CDK of mammalian cells important for G1 to S transition 
Cyclin D1 A Cyclin of mammalian cells important for G1 to S transition 
Cyclin E A Cyclin of mammalian cells important for G1 to S transition 
Cyclin A A Cyclin of mammalian cells important for S phase 
Cyclin B A Cyclin of mammalian cells important for the G2 to M transition 
E2F A transcription factor of mammalian cells important for the G1 to S 
transition 
RB A mammalian protein that inhibits E2F 
P21  A protein of mammalian cells that inhibits CDK activity 
P16 A protein of mammalian cells that inhibits CDK activity 
P53 A transcription factor of mammalian cells that activates transcription of 
DNA repair genes as well as transcription of P21 
 











1.8 Eukaryotic translation initiation factor 5A (eIF-5A) 
1.8.1 Post-translational modification of eIF-5A 
Eukaryotic translation initiation factor 5A (eIF-5A) is the only known cellular protein 
that contains the post-translationally derived amino acid, hypusine (Park et al., 1982). The 
synthesis of hypusine within eIF5A is a two-step posttranslational modification process. The 
first modification step is catalyzed by deoxyhypusine synthase (DHS), which mediates the 
transfer of a butylamine moiety from spermidine to the ε-amino group of a specific lysine 
residue, generating deoxyhypusine (Park et al., 1982). This intermediate does not accumulate 
in cells; rather, it is immediately hydroxylated at the C-2 of the incoming 4-aminobutyl 
moiety by deoxyhypusine hydroxylase (DHH), generating hypusine (Abbruzzese et al., 1985 
; Abbruzzese et al., 1986, 1988 a, b). 
1.8.2 Proposed function of eIF-5A 
Hypusine plays a key role in the regulation of eIF-5A function based on the finding 
that hypusine-deficient eIF-5A precursors have little or no activity (Park et al., 1991). 
Initially, hypusine-modified eIF-5A was isolated from immature red blood cells and named 
as a translation initiation factor because of its capability to stimulate the formation of 
methionyl-puromycin, which mimics the first peptide bond formation during protein 
synthesis, under in vitro conditions (Kemper et al., 1976). However, this proposed function 
of eIF-5A has been questioned because a similar effect on translation was not observed in 
situ (Zuk and Jacobson, 1998). Moreover, eIF-5A appears not to be required for general 
protein synthesis. For example, only marginal changes in total protein synthesis were 
observed when both isoforms of eIF-5A in yeast were mutated. This finding led to the 
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proposal that eIF-5A may be selectively required for translation of certain mRNAs (Kang 
and Hershey, 1994).  In support of this, recent research reported the identification of mRNA 
species that bind specifically to eIF-5A (Xu et al., 2004). It has been further suggested that 
eIF-5A may facilitate the translation of mRNAs required for cell proliferation (Lipowsky et 
al., 2000). This is based on the finding that hypusine modified eIF-5A is essential for 
sustained proliferation of mammalian cells (Park et al., 1994), yeast (Schnier et al., 1991), 
and archea (Jansson et al., 2000). When the levels of hypusine-modified eIF-5A were 
depleted through direct inhibition of hypusination in vivo, by biochemical means or genetic 
means, or through depletion of the polyamine spermidine, cell cycle arrest was seen at the 
G1/S boundary, and the treated cells ultimately died (Park et al.,1994 ; Jansson et al., 2000). 
The antiproliferative agent, deoxyspergualin, has also been shown to  inhibit active eIF-5A 
formation (Nishimura et al., 2002). Furthermore, when mammalian cells were treated with 
the anticancer agent, IFN-α, a reduction in hypusine synthesis occurred in parallel with 
induction of apoptosis (Caraglia et al., 2003). These observations suggest that hypusine-
modified eIF-5A is required for cell proliferation and that blocking cell division indirectly 
triggers the onset of apoptosis (Thompson et al., 2004).  
Work with plants has provided evidence for the direct involvement of eIF-5A in cell 
death.  Wang et al. (2001) found that both DHS and eIF-5A transcripts and their proteins 
increased in senescing tomato flowers, senescing tomato cotyledons, and senescing tomato 
fruit. They argued that if eIF-5A were only required for cell division, eIF-5A transcript 
would not be expected to be present at high levels in a dying tissue (Wang et al., 2001). 
These observations led to the proposal that separate isoforms of eIF-5A are involved in cell 
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division and cell death (Thompson et al., 2004). In plant systems, transgenic upregulation of 
a putative cell division isoform of eIF-5A gave rise to flowers with more petals and larger 
seeds (Thompson et al., 2004). 
Recent evidence suggests that eIF-5A functions as a nucleocytoplasmic shuttle 
protein, translocating specific mRNAs from the nucleus to the cytoplasm (Rosorius et al., 
1999). The involvement of eIF-5A in mRNA translocation is further supported by the finding 
that it serves as a cellular cofactor of HIV-1 Rev and HTLV-1 Rex transactivator proteins 
(Ruhl et al., 1993; Elfgang et al., 1999). HIV-1 Rev and HTLV-1 Rex are also 
nucloecytoplasmic shuttle proteins that mediate nuclear export of incompletely spliced and 
unspliced viral mRNAs (Smith and Greene, 1991; Pollard and Malim, 1998). 
  
1.8.3 Isoforms of eIF-5A 
Two isoforms of eIF-5A have been identified for many mammals, although three or 
more isoforms have been found in various plant species. Plant eIF-5A sequences are highly 
conserved, but they have only 50-60% amino acid identity with human, yeast and fungal eIF-
5A. However, the lysine modification site is flanked by highly conserved residues across the 
kingdoms (Wang et al., 2001). The human eIF-5A1 cDNA was first isolated in 1989 (Smit-
McBride et al., 1989), and the EIF5A1 gene was identified in 1995 (Koettnitz et al., 1995). 
Later, the human EIF5A2 gene was identified, which encodes a protein with 84% identity to 
eIF5A1 (Jenkins et al., 2001). The eIF-5A1 protein is abundantly expressed in all mammalian 
cells and human cells. Although eIF-5A2 mRNA is detectable in most cancer and human cell 
lines, eIF-5A2 protein expression is very low,  which can be attributed to inefficient 
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translation of eIF-5A2 mRNAs (Clement et al., 2003). It has been proposed that eIF-5A1 and 
eIF-5A2 are involved in apoptosis and cell proliferation, respectively (Thompson et al., 
2004).  
1.8.4 eIF-5A1 as a novel pro-apoptotic protein 
The possible role of eIF-5A1 in apoptosis has been demonstrated using tumor 
necrosis factor (TNF-α) in synergy with camptothecin. eIF-5A1 was upregulated in lamina 
cribrosa (LC) cells in response to TNF-  and camptothecin, and there was a coincident 
induction of apoptosis (Taylor et al., 2004).  Moreover, small interfering RNA (siRNA) 
against eIF-5A1 protected LC cells from apoptosis in response to  TNF-  and camptothecin, 
suggesting that eIF5A1 is a pro-apoptotic protein involved in the  death receptor pathway 
(Taylor et al., 2004). Recent research indicates that eIF-5A1 may function as a regulator of 
p53. Over-expression of eIF-5A1 induced apoptosis in human cells and resulted in up-
regulation of p53 (Li et al., 2004). Furthermore, silencing eIF-5A1 expression by siRNA 
reduced the p53 protein level (Li et al., 2004). Further analysis by reverse transcription PCR 
showed that eIF-5A1 activated p53 transcription. Moreover, the effect of eIF-5A1 on p53 
transcriptional activity was further observed by the increasing expressions of p21 and Bax, 
which are well known target genes of p53 (Li et al., 2004). In contrast, a point mutant of eIF-
5A1, which was unable to be hypusinated, was found to be functionally defective in p53 up-
regulation (Li et al., 2004). However, Taylor and colleagues have shown that eIF-5A1 is also 
able to induce apoptosis independently of p53 using RKO-E6 cells which lack functional p53 
(Catherine Taylor, unpublished results). Therefore, it can be concluded that eIF-5A1 may be 
an important regulator of both p53-dependent and –independent apoptotic pathways. 
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1.8.5 The role of eIF-5A2 as an oncogene 
The eIF-5A2 gene is located at 3q26.2, which is a region of frequent chromosomal 
alterations in many solid tumors, including ovarian, lung, oesophageal, prostate, breast, and 
nasopharyngeal cancers. In a recent study with the ovarian cancer cell line, UACC 1598, it 
was found that cell growth was inhibited when the eIF-5A2 expression level was decreased  
(Guan et al., 2004). In addition, treatment of UACC-1598 cells with antisense EIF-5A2 
decreased the cell growth (Guan et al.,2004). Moreover, anchorage-independent growth in 
soft agar has been observed in eIF-5A2-transfected NIH3T3 and LO2 cells (Guan et 
al.,2004). Furthermore, tumor formation in nude mice was observed after the injection of 
eIF-5A2-transfected LO2 cells, and over-expression of EIF-5A2 appears to be correlated with 
the advanced stages of ovarian cancer (Guan et al., 2004).  
1.8.6 Subcellular localization of eIF-5A 
Although the subcellular distribution of eIF-5A was studied to gain insight into the 
role of this protein, conflicting results were obtained. Shi et al. (1997) reported that eIF-5A is 
localized in the cytoplasm, and that treatment with the protein synthesis inhibitor, puromycin 
altered its subcellular distribution from an endoplasmic reticulum network like structure to a 
patched dotted pattern dispersed throughout the cytoplasm. They concluded that eIF-5A is 
associated with the endoplasmic reticulum through ribosomes and plays a role in protein 
synthesis (Shi et al., 1997).  Li-En and Yu (2002) reported that eIF-5A is localized in both 
the cytoplasm and the nucleus as determined by indirect immunofluorescent staining and by 
direct visualization of green fluorescent protein-tagged eIF-5A. They concluded that eIF-5A 
enters the nucleus via passive diffusion, but it does not undergo active nucleocytoplasmic 
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shuttling (Li-En and Yu, 2002). Recently, Taylor et al. (2006) reported that eIF-5A was 
predominantly localized in the cytoplasm, but that  treatment with apoptotic agents including 
actinomycin D or INF-γ and TNF-α caused a dramatic shift in localization from the 
cytoplasm to the nucleus. This indicates that eIF-5A may function as a nucleocytoplasmic 
shuttle protein during apoptosis and that re-localization of eIF-5A may play a role in the 
regulation of apoptosis. 
 
1.9 Objectives of proposed research 
There is very little information on the expression of eIF-5A1 and eIF-5A2 in response 
to apoptotic and proliferative stimuli. Thus, the overall objective of this research was to 
determine whether the expression of eIF-5A1 and eIF-5A2 correlates with the functions that 
have been tentatively ascribed to them, viz., a role for eIF-5A1 in apoptosis and a role for 
eIF-5A2 in proliferation. To this end, the temporal expression patterns of both eIF-5A1 and 
eIF-5A2 at the transcriptional and translational levels were assessed in CCD-112CoN, a 
normal human colon fibroblast cell line, and in RKO, a human colon adenocarcinoma cell 
line, in response to apoptosis induced by treatment with Actinomycin D (ActD) or sodium 
nitroprusside (SNP).  In addition, the temporal expression patterns of eIF-5A1 and eIF-5A2 
were studied at the transcriptional and translational levels in UACC-1598, a human ovarian 
cancer cell line, in response to changes in cell proliferation induced by modulation of serum 






Methods and Materials 
 
2.1 Cell culture 
Three cell lines were used for experiments reported herein . A normal human colon 
fibroblast cell line (CCD-112CoN), and a human colon adenocarcinoma cell line (RKO) 
were obtained from ATCC (American Type Culture Collection, Rockville, MD). They were 
cultured in minimum essential medium (Eagle) containing  2 mM L-glutamine and Earle's 
BSS (Sigma, Oakville, ON) , 0.1 mM non-essential amino acids (Sigma), 1.0 mM sodium 
pyruvate (Sigma) and 10% fetal bovine serum (FBS) (Sigma) .The ovarian cancer cell line 
(UACC-1598) was kindly provided by Anita Antes of the University of Medicine and 
Dentistry , New Jersey. This was cultured in 90% RPMI (Sigma) supplemented with 10% 
FBS (Sigma). All three cell lines were supplemented with 100 units/ml 
penicillin/streptomycin (Sigma) and kept at 370 C in a humidified atmosphere of 5% CO2 . 
2.2 Apoptosis  
2.2.1 Induction of apoptosis 
Cells were treated with agents known to induce apoptosis for periods of up to 24 
hours by which time  they had reached about 90% confluence. Specifically, apoptosis was 
induced by adding Actinomycin D [0.5 µg/ml (w/v) dissolved in DMSO] or sodium 




2.2.2 DeadendTM Fluorometric TUNEL assay to detect apoptosis 
The DeadEndTM Fluorometric TdT-mediated dUTP Nick-End Labelling (TUNEL) 
assay was performed according to the DeadEndTM Fluorometric TUNEL kit (Promega, 
Madison, WI). This assay measures nuclear DNA fragmentation by catalytically 
incorporating fluorescein-12-dUTP at the 3’-OH ends of DNA using the enzyme Terminal 
Deoxynucleotidyl Transferase (TdT). Following the induction of apoptosis, cells were 
washed with phosphate buffered saline (PBS) and fixed with 4% paraformaldehyde in PBS 
(w/v). The cells were then permeabilized by treatment with 0.2%  Triton X-100 (Bioshop, 
Burlington, ON) for 5 minutes and equilibrated with equilibration Buffer provided in the kit. 
Following equilibration, cells were incubated with incubation buffer containing equilibration 
buffer, nucleotide Mix and rTdT Enzyme at 37°C for 1 hour.  Subsequently,the cells were 
immersed in 2X SSC to terminate the reaction. Hoescht 33258 (blue) was used to stain the 
nuclei of all cells and TUNEL (green) was used to stain apoptotic cells only. Cells were 
visualized directly by fluorescence microscope (Carl Zeiss Meditec, Oberkochen,Germany) 
with a UV filter (UV-G 365, filter set 487902) to count nuclei of all cells and with a 
fluorescein filter (Green H546, filter set 48915) to count apoptotic cells only. The percentage 
of apoptotic cells in any field of view was calculated by dividing the number of apoptotic 
cells by the total number of cells.  
2.3 Cell proliferation  
2.3.1 Serum starvation and serum re-addition 
The effects of serum starvation and serum re-addition on cell proliferation and 
apoptosis were determined using the ovarian cancer cell line, UACC -1598. The cells were 
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cultured to about 75% confluence and then serum-starved for 3 days by replacement of the 
normal medium with medium that did not contain serum. After an additional 3 days, the 
serum-free medium was replaced with serum-containing medium and the cells were 
harvested at various intervals up to 8 hours.  
2.3.2 XTT cell proliferation assay  
Cell proliferation was measured using the XTT assay according to the Manufacturer’s 
protocol (Roche Applied Science, Mississauga, ON). This assay measures cell proliferation by 
determining the metabolic activity of viable cells. UACC-1598 cells were cultured in 96-well 
microplates until they reached about 75% confluence, and serum- starved for 3 days. The 
time points for XTT assay were as follows: 0 day, 1 day, 2 days and 3 days after serum 
starvation. After day 3, serum was added again. The time points for XTT analysis after serum 
re-addition were as follows: 1 hour, 4 hours and 8 hours.  The assay entailed incubating cells 
in  XTT solution for 4 hours so that viable cells could convert XTT to a water soluble 
formazan dye. Following  solubilization of the formazan dye in the microplate, the dye was 
quantitated using a Versamax Tunable microplate reader (Molecular Devices, Sunnyvale, 
CA) set at 490 nm and 650 nm.The absorbance indirectly indicates the number of viable 
cells.  
2.3.3 BrdU ELISA assay of cell proliferation 
Cell proliferation was also measured using the BrdU ELISA assay  according to the 
Manufacturer’s protocol (Roche Applied Science). UACC-1598 cells were cultured in 96-
well microplates until they reached about 75% confluence, and then serum-starved for 3 
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days. The time points for BrdU ELISA assay were as follows: 0 day, 1 day, 2 days, 3 days. 
After day 3, serum was added again. The time points for BrdU ELISA assay after serum re-
addition were as follows: 1 hour, 4 hours  and 8 hours.  The assay entailed labeling adherent 
cells with BrdU labeling solution for 2 hours at 370 C. Following labeling, the cells were 
fixed with FixDenat solution for 30 minutes at 15-250 C and then incubated in Peroxidase-
conjugated anti-BrdU antibody for 90 minutes at 15-250 C. The cells were then rinsed three 
times with washing solution to remove antibody conjugate. Finally, the cells were incubated 
with substrate solution at 15-250 C for 5-30 minutes or until color development was observed. 
The absorbance was measured at 370 nm and 492 nm (reference wavelength) using a 
Versamax Tunable microplate reader (Molecular Devices).  
2.4 Protein study 
2.4.1 Protein extraction 
Following the induction of apoptosis for RKO or CCD-112CoN cells, they were 
washed in Dubelco’s phosphate buffered saline (Sigma) and lysed with boiling cell lysis 
buffer containing 2% SDS (w/v)  and 50 mM Tris-HCl (pH 7.4). The cell lysate was 
collected in a microcentrifuge tube, boiled for 3 minutes and stored at -200 C until required 
for analysis. Following serum starvation and serum re-addition for UACC-1598 cells, they 
were washed with Dubelco’s phosphate buffered saline (Sigma) and lysed with boiling cell 
lysis buffer containing 2% SDS (w/v) and  50 mM Tris-HCl (pH 7.4). Each sample was then 
sonicated for 5 seconds using a Sonic Dismembrator Model 100 (Fisher Scientific, Napean , 
ON). All samples were centrifuged at 14 000 rpm for 10 minutes at 4 0 C in a microcentrifuge 
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( Heraeus Instruments, Hanau , Germany). After centrifugation, supernatants were removed 
by pipetting, transferred to new Eppendorf tubes and stored  at –20 0 C until required for 
analysis. 
 
2.4.2 Protein Quantitation 
Protein concentration was determined by the Bicinchoninic Acid protein assay kit 
(Sigma). Dilutions of bovine serum albumin (BSA, Sigma) ranging from 0 to 1000 µg/ml 
were prepared in lysis buffer from a 1 mg/ml stock of BSA. Aliquots of isolated protein 
samples were diluted 1:5, 1:10 and 1:20 in lysis buffer. Twenty five µl of each BSA standard 
was pipetted onto a polystyrene 96 well assay plate in duplicate. An equal volume of each 
diluted protein sample was also pipetted onto the plate in duplicate. A 50:1 mixture of BCA 
reagent A to reagent B (Sigma) was prepared, and 200 µl of the mixture was added to each 
well. The plate was covered with aluminium foil and incubated at 37 0 C for 30 min .The 
plate was read using a Versamax Tunable microplate reader (Molecular Devices) at 562 nm. 
The BSA standards were used to construct a standard curve that was used to determine the 
concentration of each protein sample.  
2.4.3 SDS PAGE & Western Blotting 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed using a Mini Protean II gel apparatus (BioRad, Mississaugua, ON). A 15 % 
separating gel was overlayed with 1 ml of 50% 1-butanol for 40 minutes, by which time the 
separating gel had polymerized. The 1-butanol layer was then discarded, and the stacking gel 
was layered on the top of separating gel and allowed to polymerize for 40 minutes.  For 
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western blot analysis, 5 µg (for RKO and CCD-112CoN cells ) or 10 µg (for UACC-1598 
cells ) of lysate protein was suspended  in lysis buffer [2% SDS (w/v) , 50 mM Tris-HCl (pH 
7.4)]. The resultant suspensions were then mixed 1:1 (v/v) with , loading buffer [2% SDS 
(w/v) , 10% BME (v/v) , 250 mM Tris (w/v), 30% glycerol (v/v), 0.002% bromophenol 
blue(w/v)] and boiled for 10 minutes and  centrifuged in a microcentrifuge before loading 
into the wells. The tank was filled with 1 X running buffer [25 mM Tris (w/v), 0.2 M glycine 
(w/v), 1 mM SDS (w/v), pH 8.3)], samples were loaded and electrophoresed at 0.06 amps 
until the dye front reached the bottom of the gel. Before transferring the proteins to a 
polyvinylidene difluoride (PVDF) membrane (Amersham Biosciences, Piscataway, NJ), the 
membrane was activated with methanol for 30 seconds, washed with water, and then soaked 
in cold transfer buffer [25 mM Tris (w/v), 192 mM glycine (w/v), 20% methanol (v/v)] for 
30 minutes. Following electrophoresis, the gels were also soaked in transfer buffer for 10-15 
min. Proteins were transferred to the PVDF membrane using a Trans-Blot Semi-dry Transfer 
Cell (BioRad) at 15 Volts for 36 minutes. The membrane was  incubated for 1 hour in 
blocking solution of 5% skim milk in PBS-T [137 mM NaCl (w/v), 2.7 mM KCl (w/v) , 4.3 
mM Na2HPO4 . 7H2 O (w/v) , 1.4 mM KH2 PO4 (w/v) , pH 7.3, 0.1% Tween-20(v/v)] . The 
primary antibody was diluted in a solution of 5% milk in PBS-1/2 T [137 mM NaCl (w/v), 2.7 
mM KCl (w/v) , 4.3 mM Na2HPO4 . 7H2 O (w/v) , 1.4 mM KH2 PO4 (w/v) , pH 7.3, 0.05% 
Tween-20(v/v)] and incubated with the membrane for 1 hour. The primary antibodies used 
were anti-eIF5A1 (BD Transduction Laboratories), anti-ß-actin (Calbiochem), and anti-eIF-
5A2 (Novus) at a dilution of 1:20,000, 1:10,000, 1:1000, respectively. The membranes were 
washed three times in PBS-T and incubated for 1 hour with the appropriate secondary 
 
28 
antibodies diluted in 1% milk in PBS- 1/2 T. The secondary antibodies used for eIF-5A1, ß-
actin, and eIF-5A2 were diluted 1:5000, 1:5000, and 1:3000, respectively. The membrane 
was washed and analyzed for bound antibodies.   
2.4.4 Antibody Detection 
An ECL plus western blot analysis detection kit was used according to 
Manufacturer’s protocol (Amersham Biosciences) to discern bound antibody. Detection 
solution A and B were mixed in a ratio of 40:1, and the membrane was incubated with 
detection solution for 5 minutes. After 5 minutes, detection solution was drained off, 
membrane was placed in a cassette wrapped with SeranWrap, and a sheet of autoradiography 
film (Fuji RX film) was put on the top of the membrane. The film was exposed for 15 
seconds. The film was developed and fixed immediately as described in section 2.5.2.4. 
Depending on the intensity of the band, the second film was exposed either for a longer or 
shorter period of time.  
2.4.5 Densitometry Analysis 
Densitometry analysis was performed using a Fluorchem 8000 Chemiluminescence 
and Visible Imaging System equipped with AlphaEaseFC software (Alpha Innotech, San 
Leandro, CA). Densitometry analyses were mostly performed in triplicate and in some cases 
in duplicate. The data obtained were analyzed statistically using GraphPad software.  
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2.5 RNA Isolation and Analysis 
2.5.1 RNA Extraction from Mammalian Cells 
Total RNA was extracted from mammalian cells using the GenElute Mammalian 
Total RNA Miniprep Kit (Sigma). Following the induction of  apoptosis or cell proliferation, 
confluent cells were lysed using lysis solution/2-Mercaptoethanol mixture. Lysed cells were 
pipetted into the genelute filtration column and centrifuged at maximum speed (13,000 x g) 
in a microfuge for 2 minutes to remove cellular debris. An equal volume of 70% ethanol 
(v/v) was added to the filtered lysate and pipetted thoroughly to mix. Then the ethanol/lysate 
mixture was transferred into the gene-elute binding column and centrifuged at maximum 
speed  in a microfuge for 15 seconds. The flow-through liquid was discarded. Five hundred 
µl of wash soultion1 was pipetted into the column, and the column was again centrifuged at 
maximum speed in a microfuge for 15 seconds. The flow-through liquid was discarded again. 
Then, 500 µl of ethanol containing wash solution 2 was pipetted into the column, and the 
column was again centrifuged at maximum speed in a microfuge for 15 seconds. The flow-
through liquid was discarded. Again, 500 µl of wash solution 2 was pipetted into the column 
and the column centrifuged at maximum speed in a microfuge for 2 minutes to dry the  
binding column. The flow-through liquid was discarded again. Finally, 50 µl of elution 
solution was pipetted into binding column and the column was centrifuged at maximum 
speed for 1 minute to collect RNA.  
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2.5.2 Northern Blotting 
2.5.2.1 RNA gel electrophoresis & transfer  
The isolated RNA was fractionated on a gel of 1.2% agarose containing 
formaldehyde . To this end, 5 µg of RNA from each sample was mixed with 20  ul of 
denaturing solution (56% formamide [v/v], 18% formaldehyde [v/v] , 10x MOPS [0.2 M 3-
(N-morpholino)propanesulfonic acid {MOPS}, 50 mM sodium acetate, 10 mM EDTA], 10 
% DEPC-treated water [v/v], 1 % bromophenol blue [w/v]).  In addition,  0.05 µg/µl 
ethidium bromide was included in the samples  to enable visualization  of  RNA.  
Electrophoresis was performed at 75 volts for 4 hours in 1x MOPS buffer. The fractionated 
RNA was then transferred onto a Hybond-N+ membrane (Amersham biosciences). To 
achieve this,  the gel was soaked in 0.05 N NaOH for 20 min at room temperature to partially 
hydrolyze the RNA. The gel was then rinsed with DEPC-treated water and soaked for 45 
minutes in 20 X SSC buffer [3 M sodium chloride, 300 mM sodium citrate (pH 7.0)]. A piece 
of Whatman paper was placed on a glass plate to form a support longer and wider than the 
gel.  The gel was then put on the top of support in an inverted position and surrounded with 
parafilm to prevent short-circuiting. The membrane was soaked in deionized water and then 
20 x SSC, each for 5 minutes, and placed on the top of the gel. Two pieces of Whatman 
paper soaked in 2 x SSC were  placed on top of the wet membrane. On the top of the 
Whatman papers, a stack of paper towels (5-8 cm high) was placed. Finally, a glass plate was 
put on the top of the stack and weighed down with a 500-g weight. The transfer was allowed 
to proceed overnight. Following transfer, the paper towel and blotting paper layers were 
discarded, and the correct side of the membrane was marked with pencil. After transfer, the 
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RNA was cross-linked to the damp membrane using a Gene Linker UV Chamber set at C3 
(cross-linking setting) (Biorad, Mississaugua, ON).  
2.5.2.2 Preparation of radiolabelled cDNA probe 
The transferred membrane was probed with 
32
P-labelled human eIF-5A1 (3’ UTR) 
and eIF-5A2 (3’ UTR) cDNAs. The 
32
P was incorporated into the DNA using a Hexalabel 
DNA labelling Kit according to the Manufacturer’s instructions (Fermentas Lifesciences, 
Hanover, MD). To this end, 100 µg of cDNA template, hexanucleotide (in 5X reaction 
buffer) and nuclease- free water were mixed in a tube, incubated in a boiling water bath for 
5-10 minutes and cooled on ice. Subsequently, dCTP, dTTP, dGTP mixture, [α
32
P] dATP, 
and Klenow enzyme were added to the reaction mixture, and the solution was incubated for 
10 minutes at 370 C. Then 2 µL of dNTP mix was added to the reaction mixture, and it was  
incubated for 5 minutes at 370 C. Finally, the reaction was halted by adding 0.5 M EDTA (pH 
8.0).  
2.5.2.3 Hybridization  
Before the addition of 
32
P-labelled cDNA, the membrane was prehybridized for 2 
hours at 420 C in a hybridization oven (model 2720, VWR Scientific, West Chester, PA) with 
a pre-hybridization solution [40% formamide (v/v), 20x SSC (w/v), 50x Denhart’s solution 
(w/v), 10% SDS (w/v), 7.5 mg/ml denatured salmon sperm DNA, DEPC water]. 
Subsequently, the [α
32
P] labeled cDNA probe was added to the membrane. Hybridization 
was allowed to proceed overnight at 42°C. After hybridization, the membrane was washed 
with 2x SSC + 0.1% SDS at 42°C for 2 x 15 minutes and with 1 x SSC + 0.1% SDS at 42°C 
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for 2 x 15 minutes. The membrane was wrapped in  seran wrap, placed in a cassette and 
exposed to  film (Fuji RX film) at –80°C for 1 to 7 days depending on the intensity of the 
bands.  
2.5.2.4 Membrane development 
The membrane and the film were allowed to thaw for a few hours at the room 
temperature before the film was developed. The development of the film was carried out in a 
dark room. The film was developed using commercial developer solution (Eastman Kodak 
Company, Rochester, NY). Following development, the film was washed with deionized 
water and fixed using commercial fixer solution (Eastman Kodak Company). Finally, the 
film was washed again with deionized water and bands were examined. 
2.5.3 Semi-quantitative Reverse transcriptase polymerase chain reaction (RT-PCR) 
Total RNA was isolated from human cell lines as described in section 2.5.1.  cDNA 
synthesis was performed using the Omniscript Reverse Transcriptase System for RT-PCR 
(Qiagen). Briefly, 10x buffer RT, dNTP mix (5 mM of each), 10 µm Oligo-dt primer, 10 
units/µl Rnase inhibitor, 1 µl omniscript reverse transcriptase were added to a tube for one 
reaction. If more than one RT reaction was desired, a master mix was made with the above 
reagents. Later, 8 µl of master mix was distributed to each tube and up to 2 µg RNA for each 
sample and Rnase-free water were added to each tube to make 20 µl of reaction mixture. The 
mixture was incubated at 37 0 C for 60 minutes to make first strand cDNA. Subsequently, the 
cDNA was amplified by PCR reaction in an Eppendorf mastercycler PCR Instrument 
(Eppendorf, Westbury, NY). Briefly, each PCR cycle was composed of the following steps: 
denatuation at 95 °C for 1 minute (exception,  denaturation for 5 minutes at 95 °C for the first 
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cycle only) , annealing at 55 °C for 1 minute and  extension at 72 °C for 2 minutes 
(exception,  extension for 10 minutes at 72 º C for the final cycle). The PCR was performed 
using eIF-5A1-, eIF-5A2- and β-actin- specific primers (Sigma Genosys), which were 
designed by Catherine Taylor. The sequences of the primers are as follows: eIF-5A1 forward, 
5’ CGAGTTGGAATCGAAGCCTC 3’  , eIF-5A1 reverse, 
5’GGTTCAGAGGATCACTGCTG 3’  ;  eIF-5A2 forward ,  5’ 
AAACTACCATCTCCCCTGCC 3’ ,  
 eIF-5A2 reverse, 5’ CTTCACCAGTTTCTGTCAGC 3’  ;  β-actin forward 
5’GATGATATCGCCGCGCTCGT3’, β-actin reverse, 5’ GTAGATGGGCACAGTGTGGGT 
3’ . The PCR products were electrophoretically separated on 1% agarose gels containing 
ethidium bromide and visualized using a Fluorchem 8000 Chemiluminescence and Visible 
Imaging System (Alpha Innotech).  
2.6 Preparation of Probes for Northern Analysis 
2.6.1 Human β-actin cDNA  
pCMV-XL5 containing full-length human β-actin cDNA  was obtained from Origene 
Technologies (Rockville, MD) and used as a source of β-actin probe. The vector was 
introduced into Escherichia coli DH5α cells (See Figure 3).  
2.6.2 Cloning of the 3’ UTR of Human eIF-5A1 and eIF-5A2 
The 3’ UTRs of human eIF-5A1 and eIF-5A2 were cloned by Catherine Taylor and 
Dave Powers (Dr. Thompson’s lab). To generate the 3’ UTR of  eIF-5A1, total RNA was 
isolated from RKO cells and reverse-transcribed to cDNA. The cDNA was used as a 
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template for PCR using the following primers: forward, 
5’GAGGAATTCGCTGTTGCAATCAAGGC 3’; reverse, 
5’TTTAAGCTTTGTGTCGGGGAGAGAGC 3’. The resulting PCR fragment corresponding 
to the 3’ UTR of eIF-5A1 was cloned into EcoR1/HindIII sites of  pBluescript. Likewise, to 
generate 3’ UTR of eIF-5A2 , the total RNA was isolated from RKO cells and reverse 
transcribed to cDNA. The cDNA was used as a template for PCR using the following 
primers: eIF-5A2 forward ,  5’ AAACTACCATCTCCCCTGCC 3’ ; eIF-5A2 reverse, 
3’TGCCCTACACAGGCTCAAAG 3’. The resulting PCR fragment was cloned into  pGEM 
T easy vector.  Following cloning, the insert was digested with EcoR1/Pst1 enzymes, which 
cut out the 400 bp fragment corresponding to the 3’ UTR of eIF-5A2. The resulting 400 bp 
fragment or 3’ UTR of eIF-5A2 was subcloned into EcoR1/Pst1 sites of pBluescript vector.  
The vectors containing 3’ UTR cDNA of eIF-5A1 and eIF-5A2 were then transformed into 
Escherichia coli DH5α cells.  
2.6.3 Transformation of Escherichia coli 
An aliquot of 200 µl fresh competent Escherichia coli DH5α cells was transferred 
into a microcentrifuge tube. Then, pCMV-XL5 vector containing β-actin cDNA insert or 
pBluescript vectors containing the 3’ UTR of eIF-5A1 or the 3’UTR of eIF-5A2 were added 
to the tube and the suspension incubated on ice for 30 minutes. The reaction mixture was 
then heated at 42 0 C for 90 seconds. The cells were chilled on ice for 1-2 minutes, and 800 µl 
of LB broth was added to each tube. Finally, the cells were incubated at 37 0 C for 45 minutes 
and  plated onto LB plates containing ampicillin.  
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2.6.4 Isolation of plasmid DNA 
Escherichia coli DH5α cells containing the vectors  pCMV-XL5 or pBluescript  were 
asceptically streaked on  LB agar plates [1% (w/v) tryptone , 0.5% (w/v) yeast extract, 1% 
(w/v) NaCl, 1.5% (w/v) agar] (BioShop, Burlington, ON) supplemented with 50 µg/ml 
ampicillin (BioShop). The plates were incubated overnight at 37 0 C. The following day, 
single colonies were asceptically transferred to 5 ml of LB broth [1% (w/v) tryptone, 0.5% 
(w/v) yeast extract, 1% (w/v) NaCl] supplemented with 50 µg/ml ampicillin. Bacterial 
cultures were incubated overnight in a shaker at 37 0 C.  The following day, plasmids were 
isolated using FastPlasmid  Mini kit (Eppendorf). To this end, 1.5 ml of fresh bacterial 
culture was centrifuged at 13,000 Xg for 1 minute. The supernatant was removed by 
decanting. Then, 400 µl of ice-cold complete lysis solution was added to the pellet and mixed 
properly by vortexing for 30 seconds. The lysate was incubated at room temperature for 3 
minutes. The lysate was then transferred to a spin column assembly and centrifuged for 30-
60 seconds at maximum speed in a microfuge. Subsequently,  400 µl of diluted wash buffer 
was added to the spin column assembly and centrifuged for 30-60 seconds at maximum 
speed in a microfuge. The spin column was then transferred into a collection tube. Finally, 50 
µl of elution buffer was added to the centre of spin column membrane and centrifuged at 
13,000 X g for 30-60 seconds in a microfuge. The eluted DNA was stored at -20 0 C.  
2.6.5 Restriction Enzyme Digestion  
The 3’ UTR of eIF-5A1 was cut from pBluescript using EcoR1 and HindIII 
restriction enzymes which generated a 637 bp product. The double digestion reaction was 
carried out using a common restriction buffer as it was compatible with both enzymes. The 3’ 
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UTR of eIF-5A2 was cut from pBluescript using restriction enzymes EcoR1 and BamH1, 
which generated a 400 bp product. Again, the double digestion reaction was carried out using 
a common restriction buffer. The human β-actin cDNA insert was cut from pCMV6-XL5 
using the flanking Not1 sites, which generated a 1200 bp product (see Figure 3).  
2.6.6 Purification of cDNA Probes  
Restriction enzyme digested cDNA probes were resolved by electrophoresis on a 1% 
agarose gel. The separated bands were viewed and compared with molecular weight marker 
X (Roche Diagnostics, laval, QC) to ensure that probes of the expected size were obtained. 
Then, bands were purified using a Perfectprep Gel Cleanup kit (Eppendorf). Briefly, the 
cDNA band was excised from the gel and weighed. Subsequently, 3 volumes of binding 
buffer was added for every 1 volume of gel slice, and the mixture was incubated at 50 0 C for 
5 to 10 minutes. Then, a volume of isopropanol equivalent to the volume of the gel slice was 
added and mixed by inversion or repeated pipetting. The sample was added to the spin 
column in a collection tube. The sample was spun at 10,000 x g for 1 minute, and the filtrate 
was discarded. Bound cDNA was washed by adding 750 µl of diluted wash buffer and 
centrifuging for 1 minute at 10,000 x g.  Subsequently, the filtrate was removed and 
centrifuged for an additional 1 minute at 10,000 x g. Finally, the column was placed in a new 
2 ml centrifuge tube, and 30 µl elution buffer was added and centrifuged for 1 minute at 















Figure 3. The Physical map of pCMV6-XL5. The human β-actin cDNA was directionally 
cloned between the EcoR1 and Sal1 sites. The Sal1 site was destroyed in the cloning process. 
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3.1 Quantitation of Apoptotic Cells using TUNEL Assay 
Apoptosis was induced in CCD-112CoN cells by treatment with the NO donor, 
sodium nitroprusside (SNP),  which induces apoptosis by damaging DNA and by inhibiting 
DNA synthesis (Ozen et al., 2001). The cells were treated with 3mM SNP for 0, 2, 4, 8 and 
24 hours, and apoptosis was measured using the TUNEL assay. At 24 hours, 35.7 % cells 
were undergoing  apoptosis, whereas only 0.7 %, 1.2%, 3.2% and  4.5%  of  the cells were 
undergoing  apoptosis at 0, 2, 4 and 8 hours, respectively (Figure 4).  
RKO cells were also treated with 3mM SNP for 0, 2, 4, 8 and 24 hours in order to 
induce apoptosis, and apoptosis was again quantified by TUNEL. At 24 hours, 39.6 % cells 
were undergoing  apoptosis,  whereas no cells exhibited TUNEL staining reflecting apoptosis 
at  0, 2, 4 and 8 hours (Figure 5).   
 RKO cells were also treated with Actinomycin D (ActD), which induces apoptosis by 
inhibiting DNA-dependent RNA synthesis (Leclerc et al., 2002). Apoptosis was induced by 
treating cells with 0.5 µg/ml Actinomycin D for 2, 4, 8, and 24 hours.  Treatment with 
DMSO, which was used as a vehicle control, was for 0 hours and 24 hours. At 24 hour, 23% 
cells were undergoing apoptosis,  whereas 0.3%, 1.2% and  6.1% of the cells were 
undergoing apoptosis at 2, 4 and 8 hours, respectively (Figure 6).  
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3.2 Changes in eIF-5A1 and eIF-5A2 protein and mRNA levels in RKO cells 
during SNP induced apoptosis  
In light of the proposed involvement of eIF-5A1 in apoptosis, levels of eIF-5A1 
protein were examined in RKO cells  at 0, 2, 4, 8 and 24 hours after SNP treatment. 
Moderate levels of eIF-5A1 protein were detectable after 0 hours and after 2 hours of SNP 
treatment, with a slight up-regulation after 4 and 8 hours (Figure 7). However, a decreased 
level of eIF-5A1 was observed after 24 hours of SNP treatment (Figure 7). Statistical 
analysis of ratios of eIF-5A1 protein to β-actin revealed that the up-regulation of eIF-5A1 
after 4 and 8 hours of SNP treatment was not significantly different from the level of eIF-
5A1 protein in the untreated control sample (0 hr SNP) (Figure 7).  
To examine the effects of SNP-induced apoptosis on eIF-5A1 mRNA levels, RKO 
cells were treated with SNP for 0, 2, 4, 8 and 24 hours. Figure 8 shows that eIF-5A1 mRNA 
is constitutively expressed in RKO upto 8 hours of SNP treatment and that treatment with 
SNP has no effect on eIF-5A1 transcript abundance up to 8 hours. The transcript gets 
degraded within 24 hours of SNP treatment (Figure 8) . The loading control β-actin also 
shows constitutive mRNA expression until after 8 hours of SNP treatment, and thereafter that 
transcript gets degraded (Figure 8). The disappearance of both eIF-5A1 and β-actin 
transcripts within 24 hours is probably due to DNA damage and inhibition of DNA synthesis 
by SNP, which is a NO donor (Ozen et al., 2001).  
Although the up-regulation of eIF-5A1 protein during treatment with SNP is not 
statistically significant, the up-regulation in eIF-5A1 protein levels in the absence of  a 
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corresponding up-regulation in eIF-5A1 mRNA suggests that eIF-5A1 may be post-
transcriptionally regulated.  
In order to examine eIF-5A2 protein expression during apoptosis, RKO cells were 
again treated with SNP for 0, 2, 4, 8 and 24 hours. However, eIF-5A2 protein was below 
detection levels in both control untreated cells (0 hours) and in the treated cells.     
Changes in corresponding transcript levels in RKO cells during the same treatment 
were also measured.  Initially, northern analysis was carried out using the 3’ UTR of eIF-5A2 
cDNA as a probe. However, the mRNA was below detection level due to its low abundance 
in RKO cells. As an alternative, RT-PCR was performed using eIF-5A2-specific primers in 
order to observe eIF-5A2 expression. Figure 9 shows that the eIF-5A2 mRNA is 
constitutively expressed in RKO cells up to 8 hours after SNP treatment. The housekeeping 
gene β-actin is also constitutively expressed during this time period (Figure 9).The 
disappearance of both eIF-5A2 and β-actin transcripts by  24 hours after SNP treatment  is 
probably due to DNA damage and inhibition of DNA synthesis by NO donor SNP (Ozen et 
al., 2001). The undetectable eIF-5A2 protein in presence of eIF-5A2 mRNA is attributable to 
















Figure 4. TUNEL-labeling of CCD-112CoN cells treated with Sodium nitroprusside 
(SNP).  Panel A)  For each sample, the same field was observed by fluorescence microscopy 
using two different filters.  A  UV filter was used to visualize Hoechst stained nuclei (blue), 
and a fluorescein filter was used to visualize TUNEL stained apoptotic cells (green). For  
each sample, the percentage of apoptotic cells was calculated by dividing the number of 
TUNEL stained apoptotic cells by the total number of Hoechst stained cells.  Panel B) 
Graphical illustration of the percentage of apoptotic cells. The bars are means +/- standard 
deviation from five randomly chosen fields.   *** P < 0.001, significantly different from 
control sample.  The data was analyzed with two-way ANOVA followed by Bonferroni’s 
















































Figure 5. TUNEL-labeling of RKO cells treated with sodium nitroprusside (SNP).  Panel 
A)  For each sample, the same field was observed by fluorescence microscopy using two 
different filters.  A  UV filter was used to visualize Hoechst stained nuclei (blue), and a 
fluorescein filter was used to visualize TUNEL stained apoptotic cells (green). For  each 
sample, the percentage of apoptotic cells was calculated by dividing the number of TUNEL 
stained apoptotic cells by the total number of Hoechst stained cells.  Panel B) Graphical 
illustration of the percentage of apoptotic cells. The bars are means +/- standard deviation 
from five randomly chosen fields.   *** P < 0.001, significantly different from control 

















































Figure 6. TUNEL-labeling of RKO cells treated with Actinomycin D (ActD).  Panel A)  
For each sample, the same field was observed by fluorescence microscopy using two 
different filters.  A  UV filter was used to visualize Hoechst stained nuclei (blue), and a 
fluorescein filter was used to visualize TUNEL stained apoptotic cells (green). For  each 
sample, the percentage of apoptotic cells was calculated by dividing the number of TUNEL 
stained apoptotic cells by the total number of Hoechst stained cells.  Panel B) Graphical 
illustration of the percentage of apoptotic cells. The bars are means +/- standard deviation 
from five randomly chosen fields.   *** P < 0.001, significantly different from control 


























































Figure 7. The effect of SNP treatment on eIF-5A1 protein expression in RKO cells. RKO 
cells were treated with 3 mM SNP for 0, 2, 4, 8, and 24 hours . A) Western blot analysis of 
cell lysate from RKO cells treated with SNP. Each lane contained 5 µg of protein, and the 
membrane was probed with eIF-5A1 and β-actin antibodies.  B) Plot of  the relative 
intensities of eIF-5A1 bands normalized to β-actin. Graphed data are expressed as means +/- 
standard error from three different experiments. The data was analyzed with two-way 










































































Figure 8. The effect of SNP treatment on eIF-5A1 mRNA expression in RKO cells. RKO 
cells were treated with 3 mM SNP for 0, 2, 4, 8, and 24 hours. Northern blot analysis was 
performed using the 3’ UTR of human eIF-5A1 cDNA as a probe, and human β-actin was 





























































Figure 9. The effect of SNP treatment on eIF-5A2 mRNA expression in RKO cells. RKO 
cells were treated with 3 mM SNP for 0, 2, 4, 8, and 24 hours.. Transcript levels were 
determined by semi-quantitative RT-PCR. The size of PCR products corresponding to eIF-






















































3.3 Changes in eIF-5A1 and eIF-5A2 protein and mRNA levels in CCD-112CoN 
cells during SNP induced apoptosis   
The role of eIF-5A1 protein in apoptosis was also examined in normal  CCD-112CoN 
cells.  Apoptosis was induced by treating the cells with  sodium nitroprusside (SNP) for 0, 2, 
4, 8 and 24 hours. A basal level of eIF-5A1 was detectable in control cells (0 hr SNP), and 
substantive up-regulation was evident after 2, 4, and 8 hours of SNP treatment. When the 
intensities of the eIF-5A1 bands in the Western blot were normalized to actin, it was clear 
that the increased expressions of eIF-5A1 at 2, 4, and  8 hours after SNP treatment were 
significantly different from control treatment (Figure 10). By 24 hours after treatment, eIF-
5A1 protein was no longer detectable (Figure 10).  This is consistent with the fact that SNP 
induces cell death and accompanying proteolysis. That eIF-5A1 had degraded within 24 
hours of treatment of SNP, whereas actin had not, suggests that there is selective degradation 
of SNP once apoptosis is initiated (Figure 10).  
Of particular interest is the finding that the increase in eIF-5A1 protein in normal  
CCD-112CoN cells following treatment with SNP was not accompanied by a corresponding 
increase in eIF-5A1 transcript. The Northern blot in  Figure 11 shows that eIF-5A1 mRNA is 
constitutively expressed and does not increase in abundance following treatment with SNP 
for at least 8 hours. However, by 24  hours after the initiation of SNP treatment,  levels of 
eIF-5A1 transcript decreased to undetectable levels in parallel with a corresponding decrease 
in the transcript for β-actin (Figure 11). The disappearance of both eIF-5A1 and β-actin 
transcripts after 24 hours of SNP treatment is probably due to DNA damage and inhibition of 
DNA synthesis by SNP.  The up-regulation of  eIF-5A1 protein in the absence of a 
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corresponding  up-regulation in  eIF-5A1 mRNA indicates that eIF-5A1 is post-
transcriptionally regulated . 
Unlike eIF-5A1 protein, eIF-5A2 protein was not detectable in untreated CCD-
112CoN cells. Nor was it detectable following treatment with  SNP for 0, 2, 4, 8 and 24 
hours. Again, this presumably reflects the fact that eIF-5A2 mRNA is known to be 
inefficiently translated (Clement et al., 2003).  
eIF-5A2 transcript levels in normal CCD-112CoN cells were examined by semi-
quantitative RT-PCR during treatment with SNP for 0, 2, 4, 8 and 24 hours. Figure 12 
illustrates that eIF-5A2 mRNA is constitutively expressed in CCD-112CoN in parallel with 
β-actin transcript, and does not increase in abundance for at least 8 hours following treatment 
with SNP. Thereafter, coincident with the progression of apoptosis, both  eIF-5A2 and β-
actin transcripts are undetectable  by 24 hours after the initiation of SNP treatment . This 
presumably reflects DNA damage and inhibition of DNA synthesis, which are characteristic 




















Figure 10. The effect of SNP treatment on eIF-5A1 protein expression in normal CCD-
112CoN cells. CCD-112CoN cells were treated with 3 mM SNP for 0, 2, 4, 8, and 24 hours . 
A) Western blot analysis of cell lysate from CCD-112CoN cells treated with SNP. Each lane 
contained 5 µg protein. The membrane was probed with eIF-5A1-specific antibody and actin-
specific antibody. B) Plot of  the relative intensities of eIF-5A1 bands normalized to β-actin. 
Graphed data are expressed as means +/- standard error from three different experiments. ** 
P <0.01,    *** P< 0.001 , significantly different from control treatment. The data was 














































































Figure 11. The effect of SNP treatment on eIF-5A1 mRNA expression in CCD-112CoN 
cells. CCD-112CoN  cells were treated with 3 mM SNP for 0, 2, 4, 8, and 24 hours. 
Transcript levels were determined by semi-quantitative RT-PCR. The size of PCR products 




























































Figure 12.  The effect of SNP treatment on eIF-5A2 mRNA expression in CCD-112CoN 
cells.  CCD-112CoN  cells were treated with 3 mM SNP for 0, 2, 4, 8, and 24 hours. 
Transcript levels were determined by semi-quantitative RT-PCR. The size of PCR products 





















































3.4 Changes in eIF-5A1 and eIF-5A2 protein and mRNA levels following 
treatment of RKO cells with Actinomycin D  
 The effects of Actinomycin D treatment, which also induces apoptosis, on eIF-5A1 
protein expression was examined in RKO cells. The cells were treated with Actinomycin D 
dissolved in DMSO for  2, 4, 8 and 24 hours, and  treatment with DMSO (0 and 24 hours ) 
was used as a vehicle control.  A modest level of eIF-5A1 protein was detectable after 0 and 
2 hours of Actinomycin D treatment, and slight up-regulation was observed after 4, 8 and 24 
hours of treatment (Figure 13). However, when the level of eIF-5A1 expression was 
expressed as a ratio of corresponding levels of  β-actin, the up-regulation relative to the 
DMSO control at 0 hours and 24 hours was not statistically significant (Figure 13).   
Changes in eIF-5A1 transcript levels following treatment of RKO cells with 
Actinomycin D were also determined. The Northern blot in Figure 14 illustrates that eIF-5A1 
mRNA is constitutively expressed until 8 hours after Actinomycin D treatment. Thereafter, 
the transcript apparently gets degraded and is not detectable by 24 hours after the initiation of 
Actinomycin D treatment (Figure 14). This reflects a general decline in transcription rather 
than selective inhibition of eIF-5A1 transcription is apparent from the finding that  the β-
actin transcript also decreases  to undetectable levels by 24 hours after initiation of the 
Actinomycin D treatment (Figure 14). The disappearance of both eIF-5A1 and β-actin 
transcripts at 24 hour is probably due to the inhibition of transcription by Actinomycin D 
(Leclerc et al., 2002). The up-regulation in eIF-5A1 protein levels in the absence of  a 
corresponding up-regulation in eIF-5A1 mRNA suggests that eIF-5A1 may be post-




 In a similar vein, the effets of Actinomycin D – induced apoptosis in RKO cells on 
eIF-5A2 expression were also examined. In this case, the cells were again treated with 
Actinomycin D for 2, 4, 8 and 24 hours and with DMSO for 0 and 24 hours as a control. The 
eIF-5A2 protein level was below detection at all time points, again reflecting the very low 
levels of this protein in RKO cells.  Furthermore, eIF-5A2 transcript was not detectable by 
Northern blotting. However, eIF-5A2 transcript was detectable by semi-quantitative RT- 
PCR using eIF-5A2 specific primers.  The semi-quantitative RT-PCR data indicated that eIF-
5A2 mRNA is detectable in untreated RKO cells (0 hr and 24 hours DMSO) and that its 
abundance remains essentially unchanged for at least  8 hours after the initiation of  
Actinomycin D treatment (Figure 15). The housekeeping gene β-actin is also constitutively 
expressed during this initial period of Actinomycin D treatment (Figure 15).  However, both 
transcripts are undetectable after 24 hours of Actinomcyin D treatment (Figure 15), which 
presumably reflects the known inhibitory effect of Actinomycin D on transcription (Leclerc 


















Figure 13. The effect of Actinomycin D treatment on  eIF-5A1 protein expression in 
RKO cells. RKO cells were treated with 0.5 µg/ml Actinomycin D for 2, 4, 8, and 24 hours. 
DMSO (0 and 24 hours) was used as a vehicle control . A) Western blot analysis of cell 
lysate from RKO cells treated with ActD. Each lane contained 5 µg protein. The membrane 
was probed with eIF-5A1-specific antibody and actin-specific antibody B) Plot of  the 
relative intensities of eIF-5A1 bands normalized to β-actin. Graphed data are expressed as 
means +/- standard deviation from two different experiments. The data was analyzed with 














































































Figure 14. The effect of ActD treatment on eIF-5A1 mRNA expression in RKO cells. 
RKO cells were treated with 0.5 µg/ml ActD for 2, 4, 8, and 24 hour. DMSO was used as a 
vehicle control for 0 and 24 hours. Northern blot analysis was performed using 3’ UTR of 
human eIF-5A1 cDNA as a probe , and human β-actin was used as a loading control. The 









































































Figure 15. The effect of Actinomycin D treatment on eIF-5A2 mRNA expression in 
RKO cells. RKO cells were treated with 0.5 µg/ml of ActD for 2, 4, 8, and 24 hours. DMSO 
(0 and 24 hours) was used as a vehicle control. A) Transcript levels were determined by 
semi-quantitative RT-PCR. The size of PCR products corresponding to eIF-5A2 and β-actin 
transcripts were 345 bp and 500 bp, respectively. B) Densitometry analysis of eIF-5A2 
mRNA expression relative to β-actin. Graphed data are expressed as means +/- standard error 
from three different experiments. The treated samples were not significantly different from 
control samples. The data was analyzed with two-way ANOVA followed by Bonferroni’s 







































































3.5 Changes in eIF-5A1 and eIF-5A2 mRNA and protein levels in normal CCD-
112CoN cells in response to Actinomycin D treatment  
 To examine the effects of apoptosis on eIF-5A1 mRNA levels in normal CCD-
112CoN cells, apoptosis was induced by treatment with  0.5 µg/ml Actinomycin D for 0, 1, 
4, 8 and 24 hours. Figure 16 shows that the eIF-5A1 mRNA is detectable in untreated cells 
and that its abundance does not change for at least 8 hours after the initiation of  
Actinomcyin D treatment.  However, after 24 hours of Actinomycin D treatment, eIF-5A1 
transcript was not detectable (Figure 16).  Levels of β-actin transcript showed a similar 
pattern during the Actinomycin D treatment (Figure 16). The disappearance of both eIF-5A1 
and β-actin transcripts at 24 hours is presumably due to the inhibition of transcription by 
Actinomycin D.  
 In subsequent experiments designed to determine the effects of Actinomycin D 
treatment on eIF-5A1 and eIF-5A2 protein levels and on eIF-5A2 mRNA level, technical 
problems were encountered. Specifically, CCD-112CoN cells did not undergo apoptosis in 
response to the application of Actinomycin D, even when the concentration was increased 
0.5 µg/ml to 5 µg/ml. New CCD-112CoN cells were obtained from ATCC, but to no avail.  
Therefore, eIF-5A1 and eIF-5A2 protein data and eIF-5A2 mRNA data using this agent are 
not available.   
 



















Figure 16. The effect of Actinomycin D treatment on eIF-5A1 mRNA expression in 
CCD-112CoN cells. CCD-112CoN cells were treated with 0.5 µg/ml ActD for 0, 1, 4, 8, and 
24 hours. Northern blot analysis was performed using 3’ UTR of human eIF-5A1 cDNA as a 


















































3.6 Effect of serum starvation and serum re-addition on cell proliferation and 
eIF-5A1 and eIF-5A2 expression utilizing UACC-1598 cells 
 In order to investigate the effects of serum starvation and serum-readdition on cell 
proliferation, an ovarian cancer cell line (UACC-1598), which contains a detectable level of 
eIF-5A2 was grown to about 70% confluence and then serum- starved for 3 days. Samples 
were analyzed using the BrdU ELISA assay to quantify cell proliferation after 0, 1, 2, and 3 
days  of serum- starvation. After day 3, serum was added again, and samples were analyzed 
using the BrdU ELISA after 1, 4, and 8 hours of serum re-addition. The BrdU ELISA 
revealed that cell proliferation increases at day 1 after serum starvation, and then starts 
decreasing gradually until day 3 of serum starvation (Figure 17). Moreover, cell proliferation 
continues to decrease even 8 hours after serum re-addition (Figure 17).  
 To confirm the results obtained by BrdU ELISA, the XTT proliferation assay was 
also performed. Figure 18 shows the same trend as obtained by BrdU ELISA. The highest 
cell proliferation was observed at day 1, and thereafter begins to decline. Even after serum 
re-addition, the cell proliferation continues to decrease (Figure 18).  
 In order to investigate whether decreased cell proliferation coincides with cell death, 
UACC-1598 cells were grown to about 70% confluence and then serum- starved for 3 days. 
After day 3, serum was added again, and apoptosis was measured using the TUNEL assay. 
The TUNEL assay indicated that approximately 6.5%, 10.2%, 10.6%, 22%, 22.5%, 23% and 
25% of the cells were undergoing apoptosis at 0 day, 1 day, 2 days, and 3 days after serum 
starvation and at 1 hour, 4 hours and 8 hours after serum-readdition, respectively. Thus it 
would appear that in absence of serum, cells start undergoing apoptosis, and serum-
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readdition does not reverse this process and re-initiate cell proliferation (Figure 19). The 
morphology of UACC-1598 cells following serum withdrawal and re-addition was also 
examined by microscopy using a halogen light source. Figure 19 reveals that initially the 
density of cell growth was very high with cells clustered together, but upon serum 
withdrawal  the cells detach from each other and from the plate and become rounded.   This  
morphology does not change even after serum re-addition, which is consistent with the 
TUNEL data indicating that the cells are undergoing apoptosis.  
 To examine the effect of cell proliferation on eIF-5A1 mRNA expression, UACC-
1598 cells were grown to about 70% confluence and then serum- starved for 3 days. After 
day 3, serum was added back, and mRNA levels were determined 8 hours thereafter. Figure 
20 illustrates that serum starvation and re-addition do not have any effect on eIF-5A1 mRNA 
expression as no change in transcript abundance was observed. 
 The effect of cell proliferation on eIF-5A1 protein expression was also investigated. 
UACC-1598 cells were grown to about 70% confluence and then serum- starved for 3 days. 
Protein samples were collected after 0, 1, 2, and 3 days of serum starvation. After day 3, 
serum was added back, and samples were collected 1, 4, and 8 hours thereafter. eIF-5A1 and 
eIF-5A2 proteins were both  detectable after probing membrane with eIF-5A1 specific- 
antibody (Figure  21). The cross-reaction of eIF-5A1- specific antibody with eIF-5A2 protein 
is not surprising inasmuch as eIF-5A1 and  eIF-5A2 are 84% identical at the amino acid 
level. Figure 21 shows that both isoforms respond in a similar manner to serum starvation 
and serum re-addition. Both are detectable until day 3 of serum starvation, but they disappear 
by day 3 and do not reappear even after the re-addition of serum. In addition, both seem to be 
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up-regulated at day 1 after serum starvation, which is temporally coincident with the onset of 
apoptosis.   It was hypothesized that upon serum re-addition, cell proliferation would 
increase and the roles of eIF-5A1 and eIF-5A2 in response to cell proliferation could be 
clarified. Since serum re-addition did not increase cell proliferation, the role of eIF-5A1 and 
eIF-5A2 in cell proliferation still remains uncertain. The up-regulation  of eIF-5A1 protein in 
absence of corresponding up-regulation of  eIF-5A1 mRNA clearly indicates that eIF-5A1 
may be post-transcriptionally regulated.  
To examine the effect of cell proliferation on eIF-5A2 mRNA expression, UACC-
1598 cells were grown to about 70% confluence and then serum- starved for 3 days. After 
day 3, serum was added back, and mRNA levels were determined 8 hours thereafter. Figure 
22 illustrates that serum starvation and re-addition do not have any effect on eIF-5A2 mRNA 
expression as no change in transcript abundance was observed.The up-regulation  of eIF-5A2 
protein in absence of corresponding up-regulation of eIF-5A2 mRNA clearly indicates that 





















Figure 17. BrdU ELISA assay of cell proliferation for UACC-1598 cells. UACC-1598 
cells were grown to about 70% confluence and then serum- starved for 3 days. Samples were 
analyzed using the BrdU ELISA assay after 0, 1, 2, and 3 days of serum- starvation. After 
day 3, serum was added back, and samples were analyzed using the BrdU ELISA assay after 
1, 4, and 8 hours of serum re-addition. Graphed data were expressed as means +/- standard 
deviation for two experiments performed in quadruplicate. *** P < 0.001, significantly 
different from control sample (0 day). The data was analyzed with two-way ANOVA 
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Figure 18. XTT assay of cell proliferation for UACC-1598 cells. UACC-1598 cells were 
grown to about 70% confluence and then serum- starved for 3 days. Samples were analyzed 
using the XTT assay after 0, 1, 2, and 3 days of serum- starvation. After day 3, serum was 
added back, and samples were analyzed using the XTT assay after 1, 4, and 8 hours of serum 
re-addition. Graphed data were expressed as means +/- standard error for two experiments 
performed in quadruplicate. ** P < 0.01, significantly different from control sample (0 day). 


























































Figure 19.  TUNEL-labeling of UACC-1598 cells after serum- starvation and serum-re-
addition.  Panel A) For each sample, the same field was observed by two different filters 
using a fluorescence microscope. A UV filter was used to visualize Hoechst stained nuclei 
(blue), and a fluorescein filter was used to visualize TUNEL stained apoptotic cells (green). 
For each sample, the percentage of apoptotic cells was calculated by dividing the number of 
TUNEL- stained apoptotic cells by the total number of Hoechst- stained cells. The cell 
morphology was observed using a halogen light source. Images for halogen source are not 
from the same field as TUNEL and Hoechst. Panel B) Graphical representation of the 
percentage of apoptotic cells. Graphed data are expressed as means +/- standard deviation 
from five randomly chosen fields.** P < 0.01, * P < 0.05, significantly different from control 
sample (0 day).  The data was analyzed with two-way ANOVA followed by Bonferroni’s 






























































































































Figure 20. The effect of serum- starvation and serum-re-addition on eIF-5A1 mRNA 
expression in UACC-1598 cells . UACC-1598 cells were grown to about 70% confluence 
and then serum- starved for 3 days. RNA samples were collected after 0, 1, 2, and 3 days of 
serum- starvation. After day 3, serum was added back, and samples were collected after 1, 4, 
and 8 hours of serum re-addition. Total RNA was isolated at each time point.  Semi-
quantitative RT-PCR was performed using specific  primers. The size of the PCR products 
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Figure 21. The effect of serum starvation and serum re-addition on eIF-5A1 and eIF-
5A2 protein expression. UACC-1598 cells were grown to about 70% confluence and then 
serum- starved for 3 days. Protein samples were collected after 0, 1, 2, and 3 days of serum- 
starvation. After day 3, serum was added back and samples were collected after 1, 4, and 8 
hours thereafter. Panel A) western analysis of UACC-1598 cell lysates. Each lane contained 
10 µg of protein, and the gel was probed with eIF-5A1 antibody. The corresponding 
Comassie Blue- stained gel is also presented. The eIF-5A1 and eIF-5A2 proteins are 18 and 
20 kDa in size, respectively. Panel B) Densitometry analysis of eIF-5A1 and eIF-5A2 
expression. Graphed data were expressed as means +/- standard deviation for n=2. The 
treated samples were not significantly different from the control sample (0  day). The data 
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Figure 22. The effect of serum starvation and serum re-addition on eIF-5A2 mRNA 
expression. Ovarian cancer cells (UACC-1598) were grown to about 70% confluence and 
then serum starved for 3 days. RNA samples were collected after 0, 1, 2, and 3 days of serum 
starvation. After day 3, serum was added back, and samples were collected 1, 4, and 8 hours 
thereafter. Semi-quantitative RT-PCR was performed using specific sets of primers as 
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The objective in this study was to elucidate the role of human eIF-5A in apoptosis 
and cell proliferation. There are two isoforms of eIF5A in the human genome, designated 
eIF-5A1 and eIF-5A2. Most of the studies to date have been with eIF-5A1, and roles in both 
apoptosis and cell proliferation have been ascribed to it (Taylor et al., 2004 ; Park et al., 
1994). Little has been done with eIF-5A2, presumably in part because it is expressed at very 
low levels in most cells and tissues (Clement et al., 2003).  There is evidence that eIF-5A2 is 
expressed at high levels in ovarian cancer cells and that it may be an oncogene (Guan et al., 
2004). Of particular importance in interpreting these studies is that eIF5A is post-
translationally modified through two reactions in which a conserved lysine in eIF-5A1 is 
converted to hypusine (Park et al., 1982). The first reaction mediated by deoxyhypusine 
synthase results in the formation of deoxyhypusinated eIF-5A1, and the second, mediated by 
deoxyhypusine hydroxylase, results in the formation of hypusinated eIF-5A1 (Park et al., 
1982).  Thus, there are three forms of eIF-5A1 protein present in cells, unhypusinated eIF-
5A1, deoxyhypusinated eIF-5A1 and hypusinated eIF-5A1.   Although it is generally 
assumed that hypusinated form of eIF-5A1 is physiologically active, there is at least one 




In the present study, apoptosis was induced by treatment with Actinomycin D. The 
ability of Actinomycin D to induce apoptosis is well established, and it appears to do so by 
blocking the movement of RNA polymerase and interfering with DNA-dependent RNA 
synthesis (Leclerc et al., 2002). Apoptosis was also induced by NO donor sodium 
nitroprusside , which induces  apoptosis by damaging DNA and inhibiting DNA synthesis 
(Gordana  et al., 2004). Two human cell lines were used for apoptosis study, RKO cells 
which are colon adenocarcinoma cells and CCD-112CoN, which are normal colon fibroblast 
cells.   
In response to Actinomycin D treatment, eIF-5A1 and β-actin transcripts were both 
detectable in RKO cells and CCD-112CoN cells and showed no change in abundance during 
first 8 hours of Actinomycin D treatment. However, 24 hours after the initiation of 
Actinomycin D treatment, by which time the extent of apoptosis had increased, transcripts 
for both the housekeeping gene, β-actin, and eIF-5A1 were undetectable. This may be 
attributable to the fact that Actinomycin D inhibits transcription. It does so by forming a 
stable complex with single-stranded DNA and blocking the movement of RNA polymerase, 
thereby  interfering with DNA-dependent RNA synthesis (Leclerc et al., 2002). β-actin is a 
commonly used housekeeping gene because its cognate protein  remains constant throughout 
the cell cycle (Leclerc et al., 2002). In light of this, it seems reasonable to conclude that the 
depletion of  β-actin mRNA and eIF-5A1 mRNA within 24 hours of Actinomycin D 
treatment largely reflects inhibition of transcription. This contention is further supported by 
the finding that the half-life of β-actin mRNA following treatment with Actinomycin D has 
been reported to be 6.6 hours for  human CCRF-CEM and  13.5 hours for human Nalm-6 
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cells (Leclerc et al., 2002). The finding in the present study that β-actin mRNA declined to 
undetectable levels within 24 hours of Actinomycin D treatment is consistent with these 
findings. 
Of particular interest is the finding for both RKO cells and CCD-112CoN cells that, 
although there was no change in eIF-5A1 transcript during Actinomycin D –induced 
apoptosis, there was an up-regulation of eIF-5A1 protein. It was not possible to determine 
whether this was also the case for eIF-5A2 protein, because levels of this protein were below 
detection limits. Cellular levels of eIF-5A2 are generally low, and this has been attributed  in 
part to inefficient translation of eIF-5A2 mRNA (Clement et al., 2006). Clement and his 
colleagues observed that eIF-5A2 precursor was synthesized at a level comparable to that for 
eIF-5A1 precursor, which led them to propose  that negative cis elements retarding  the 
translation of eIF-5A2 mRNA may reside in the 5’ UTR or 3’ UTR. Moreover, sucrose 
gradient fractionation of cytopalsmic RNA  revealed that  only a small proportion of total 
eIF-5A2 mRNA was associated with the polysomal fraction, compared to a much larger 
proportion of eIF-5A1 mRNA (Clement et al., 2006).  
 The effects of apoptosis on the expression of eIF-5A1 were also determined using 
SNP, which is a strong source of NO that serves as a powerful inducer of apoptosis. For both 
RKO (cancer) and CCD-112CoN (normal) cells, eIF-5A1 and β-actin transcripts were readily 
detectable in untreated cells and did not change in abundance within 8 hours of treatment 
with SNP. However, by 24 hours after the initiation of SNP treatment, the transcripts for both  
β-actin and eIF-5A1 had decreased to levels that were below detection. This presumably 
reflects DNA damage and inhibition of transcription, both of which are known to be caused 
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by SNP (Gordana  et al., 2004). Likewise, β-actin and eIF-5A2 mRNA were found to be 
constitutively expressed for 8 hours, and they disappeared after 24 hours of SNP treatment 
during apoptosis in both cells. The disappearance of transcripts again attributable to the 
inhibition of DNA synthesis by SNP.  
 By contrast, eIF-5A1 protein was found to be up-regulated in both RKO and CCD-
112CoN cells during apoptosis induced by SNP treatment. In fact, eIF-5A1 in normal cells 
(CCD-112CoN) was found to be up-regulated more than in cancer cells (RKO). It is possible 
that  eIF-5A1may be mutated and hence non-functional in cancer cells. Relevant to this, 
Hong Ming  sequenced the coding region of eIF-5A1 from mouse alveolar lung tumor and 
found that the coding region of eIF-5A1 was not mutated in the tumor samples (Dr. 
Thompson’s lab, unpublished data). Although it is not possible to generalize from this 
observation to other types of cancer, it would appear that, at least in this mouse lung tumor, 
eIF-5A1 is functional. Recently, however, an interaction between eIF-5A1 and syntenin has 
been established (Li et al., 2004). Syntenin is found to be over-expressed in advanced 
metastatic  melanomas (Helmke et al., 2004). Therefore, it is possible that in cancer cells, 
syntenin binds to eIF-5A1 and interferes with its function in inducing apoptosis. eIF-5A2 
protein was again below detection levels in both RKO cells and CCD-112CoN cells 
following treatment with SNP.  
It is noteworthy that in response to Actinomycin D-induced apoptosis  and SNP 
induced apoptosis eIF-5A1 protein was up-regulated in the absence of a corresponding up-
regulation of its transcript. These observations suggest that eIF-5A1 protein synthesis is post-
transcritionally regulated..  The central concept of post-transcriptional regulation is that the 
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translation of a given mRNA occurs in the absence of a corresponding change in the steady-
state level of that mRNA (Xi et al., 2006). Post-transcriptional regulation provides the cell 
with a more precise, immediate, and energy-efficient way of translating mRNAs without the 
need for transcriptional activation and subsequent mRNA processing steps (Xi et al., 2006). 
Moreover, post-transcriptional control provides the cell with greater flexibility in responding 
to various genotoxic stresses (Xi et al., 2006).  
Expression of the tumor-suppressor gene, p53, is regulated through a post-
transcriptional mechanism. Evidence supporting this includes the finding that there is  
increased expression of p53 protein in the absence of any change in the level of p53 mRNA 
during ultraviolet light radiation and gamma irradiation (Fu and Benchimol, 1997 ; Mazan-
Mamczarz et al., 2003 ; Fu et al., 1999) . Moreover, the increase in p53 protein  was  
accompanied by enhanced association of   p53 mRNA with large polysomes, further 
supporting the contention that there was an increase in its translation  (Fu and 
Benchimol,1997). There is also evidence that p53 post-transcriptional regulation entails 
association of the 3’UTR of p53 mRNA with the RNA binding protein, HuR, which 
enhances p53 translation in response to ultraviolet light irradiation (Mazan-Mamczarz et al., 
2003). In addition,  a cis acting element in the 3’ UTR of p53 mRNA has been identified 
which appears to  mediate translational repression of p53 mRNA. In response to gamma-
radiation, the inhibitory effect of the repressor element on translation is relieved,  and p53 
protein is up-regulated without the up-regulation of p53 mRNA (Fu et al., 1999).  
Post-transcriptional regulation of proteins required for apoptosis is advantageous 
because the process of programmed cell death can be initiated quickly. In the specific case of 
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eIF-5A1, cells can quickly translate eIF-5A1 without the need to activate transcription. 
Recent evidence suggests that post-transcriptional regulation of eIF-5A1 may be mediated by 
p53 (Xi et al., 2006). In addition to its function as a transcription factor, p53 also acts as an 
RNA-binding protein capable of regulating its own mRNA translation (Fu et al., 1996) as 
well as  regulating the expression of other cellular mRNA transcripts at the post-
transcriptional level (Miller et al., 2000). Xi et al. (2006) suggest that p53 affects gene 
expression at the post-transcriptional level either through miRNAs or its RNA-binding 
capability, although they have not discussed the detailed mechanism. It is possible that as an 
RNA binding protein, p53 binds to the 3’ UTR of eIF-5A1 mRNA and enhances eIF-5A1 
translation in response to apoptotic agents such as Actinomcyin D and sodium nitoprusside. 
Another  possibility is that an RNA binding protein such as HuR may mediate eIF-5A1 post-
transcriptional regulation through association with the 3’ UTR of eIF-5A1 mRNA. It is also 
possible that the increased expression of eIF-5A1 protein in the absence of increased eIF-
5A1 mRNA might occur through an enhanced association of eIF-5A1 mRNA with large 
polysomes. Like p53, there could be a cis acting element in the 3’ UTR of eIF-5A1 mRNA 
which mediates translational repression of eIF-5A1 mRNA. In response to apoptotic agents 
such as Actinomycin D and Sodium nitoprusside, the inhibitory effect of this repressor 
element on translation may be relieved, allowing up-regulation of  eIF-5A1 protein in the 
absence of a corresponding  up-regulation of eIF-5A1 mRNA.  
The serum- starvation and serum re-addition experiments were designed to examine 
the effects of cell proliferation on the expression of eIF-5A1 and eIF-5A2 protein and 
mRNA. In many cell types, serum- starvation leads to cell cycle arrest in the G0–G1 phase 
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and/or apoptosis after prolonged incubation (Yoshida and Beppu 1988; Fukami-Kobayashi 
and Mitsui 1999 ; Hasan et al. 1998). Serum re-addition causes arrested cells to re-enter the 
cell cycle and to synthesize DNA within a few hours (Campisi et al., 1984). In other words, 
serum re-addition re-induces cell proliferation within a few hours. Moreover, it has been 
shown that, upon serum re-addition, eIF-5A expression is induced and protein can be 
detected after a few hours of serum re-addition (Chen and Chen, 1997). Based on this 
finding, the serum- depletion and re-addition experiments conducted in the present study to 
clarify the relative roles of eIF-5A1 and eIF-5A2 in cell proliferation.  The ovarian cancer 
cell line, UACC-1598, was used for these experiments as it was observed previously to 
contain detectable amounts of eIF-5A2 (Clement et al., 2003).  Both BrdU and XTT data 
obtained using UACC-1598 cells  revealed  that cell proliferation decreases in response to 
serum starvation, and continues to decline even after 8 hours of serum re-addition. From 
TUNEL data, it was confirmed that the decrease in cell proliferation coincides with the 
induction of apoptosis.The reason for the discrepancy between the finding in this study that 
the cells did not re-initiate proliferation upon serum re-addition, whereas in the study of Chen 
and Chen (1997) re-initiation of cell proliferation was observed when serum was re-added,  
may reflect the fact that different cell lines were used in the two studies. In the present study, 
it is possible that  the cells had  reached a  later stage of apoptosis, and serum re-addition was 
not able to reignite cell proliferation.  Another possibility is  that UACC-1598 cells  require 
more than 8 hours after serum re-addition to re-enter the cell cycle and start DNA synthesis 
leading to proliferation.  
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Of particular interest is the finding that there was no change in the levels of either 
eIF-5A1 transcipt or eIF-5A2  transcript in UACC – 1598 cells in response to serum 
depletion or serum re-addition.  Yet, eIF-5A1 protein and eIF-5A2 protein both increased in 
abundance within 1 day of serum starvation before declining again. Moreover, this increase 
in eIF-5A1 protein and eIF-5A2 protein coincided with the induction of apoptosis as 
measured by TUNEL and a subsequent decline in viable cells. The decrease in viable cells 
was evident from the finding that the cells detached and  assumed a rounded phenotype, and 
that there was a decline in cell division measured by the BrdU ELISA assay  and a decline in 
cell viability measured by the XTT assay. Moreover, there was no resumption of cell division 
and no increase in cell viability following re-addition of serum, and there was no increase in 
eIF-5A1 or eIF-5A2 protein levels.  
There are several important findings that can be inferred from these data. First, levels 
of eIF-5A1 and eIF5A2 protein change in parallel in response to serum- depletion. This 
suggests that, at least in UACC – 1598 cells, their translation is commonly regulated. Second, 
eIF-5A1 and eIF-5A2 both exhibit up-regulation in response to serum- depletion in the 
absence of a corresponding increase in transcript. This suggests that, like eIF-5A1, eIF-5A2 
is also post-transcriptionally regulated. Third, both proteins are up-regulated in parallel 
during serum- starvation just prior to the onset of apoptosis leading to loss of cell viability 
and cell death. This raises the possibility that they may both be involved in apoptosis.  There 
is growing evidence from studies with cell lines that eIF-5A1 is able to induce apoptosis 
(Taylor et al., 2004 ; Taylor et al., 2006). Moreover, Hong Ming has shown that cells 
transfected with adenovirus constructs of eIF-5A1 or eIF-5A2 undergo apoptosis (Dr. 
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Thompson’s lab, unpublished data). In addition, eIF-5A1 has been shown to be a strong and 
effective anti-cancer therapy in studies with tumorigenic mice (Songmu Jin, Hong Ming, and 
Catherine Taylor, unpublished data, Dr. Thompson’s lab). The present results are consistent 
with the contention that eIF-5A2 is also involved in the induction of apoptosis and the two 
isoforms of human eIF5A may have redundant functions. 
The roles of eIF-5A1 and eIF-5A2 in cell proliferation remain unclear. It was not 
possible to evaluate whether they play a role in cell proliferation in the present study because 
there was no resumption of cell proliferation by UACC – 1598 cells when serum was added 
back after a period of serum depletion. Rather, the cells continued to undergo apoptosis and 
lose viability.  Several previous reports have implicated the role of eIF-5A1 in cell 
proliferation (Park et al., 1994 ; Jansson et al., 2000) . These studies mainly involved 
demonstrating that inhibitors of hypusination block cell division. However it was not made 
clear in these studies that the suppression of cell division observed was not an indirect effect 
of the inhibitors unrelated to their ability to inhibit hypusination of eIF5A (Taylor et al., 
2006). The present study on the other hand supports previous reports (Taylor et al., 2004 ; 
Taylor et al., 2006) that eIF-5A1 is involved in the induction of apoptosis  and, in addition , 
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